Pharmaceutical Technology

APRIL 24, 2023

While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 billion in 2029.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

European Pharmaceutical Review

AUGUST 21, 2023

Submission for US FDA regulatory approval, anticipated to be received by the end of 2023, further drove this progress, GlobalData noted. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted.

Biopharma 79

Biopharma Marketing Sales Medicine 79

pharmaphorum

SEPTEMBER 30, 2022

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. Viatris is seeking FDA approval to market generic versions of both Januvia and Janumet in the US. The US patent (No.

Marketing 57

Marketing Sales Competition FDA 57

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

Pharmaceutical Technology

MAY 16, 2023

million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Sanofi and Regeneron’s market capitalisation grew by 12.4%

Marketing 52

Marketing Sales Pharma Leads 52

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.

Sales 59

Sales Competition Marketing Patients 59